BEGIN:VCALENDAR
VERSION:2.0
METHOD:PUBLISH
PRODID:-//Telerik Inc.//Sitefinity CMS 15.4//EN
BEGIN:VTIMEZONE
TZID:UTC
BEGIN:STANDARD
DTSTART;VALUE=DATE:20250101
TZNAME:UTC
TZOFFSETFROM:+0000
TZOFFSETTO:+0000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DESCRIPTION:Date:&nbsp\;Thursday 26th October 2023\nTime:&nbsp\;15:00-16:00
  BST\nLocation:&nbsp\;Online\nSpeaker:&nbsp\;Yunda Huang\, Ph.D&nbsp\;\n\n
 Who is this event intended for?&nbsp\;Statisticians/researchers working in
  vaccine\, monoclonal antibody or infectious diseases.\nWhat is the benefi
 t of attending?&nbsp\;This webinar will help statisticians/researchers wor
 king in the vaccine and monoclonal antibody fields better understand each 
 other's work and the potential synergies in collaborating with each other.
 \nRegistration\nThis event is free to both Members of PSI and Non-Members.
 \nTo register for this event\, please&nbsp\;click here.&nbsp\;\nOverview\n
 The speaker will share her experience in extending/innovating methodology 
 and concepts developed in vaccine statistics to the analyses of pre-effica
 cy and efficacy trials of monoclonal antibodies.\nPresentation Abstract\nC
 atalysed by the rapid research and development of preventive and therapeut
 ic monoclonal antibodies in multiple biomedical fields\, there is an incre
 asing demand of innovative statistical research in the design and analysis
  of monoclonal antibody studies. Published in 2022\, a new biomarker\, cal
 led PT80 was identified as a promising surrogate endpoint to reliably pred
 ict the ability of broadly neutralizing monoclonal antibodies to prevent a
 cquisition of HIV-1. Findings from this study build on the proof-of-concep
 t Antibody Mediated Prevention (AMP) trials showing that an mAb called VRC
 01 was effective in preventing the acquisition of some &ndash\; but not al
 l &ndash\; HIV strains. In this talk\, I will share our journey in reachin
 g the discovery of PT80 for VRC01 via extending/innovating methodology and
  concepts from vaccine statistics to the design and analysis of monoclonal
  antibody studies.\nSpeaker details\n\n\n\n    \n        \n            \n 
            Speaker\n            \n            \n            Biography\n   
          \n        \n        \n            \n            \n            Dr.
  Yunda Huang\n            \n            \n            Dr. Huang&rsquo\;s r
 esearch areas have focused on the statistical design and analysis of vacci
 ne clinical trials\, monoclonal antibody clinical trials and immunological
  biomarker studies related to the prevention and treatment of HIV and othe
 r infectious diseases. She has worked closely with academic\, regulatory a
 nd industrial collaborators in providing statistical leadership for 20+ ph
 ase 1/2/2b pre-efficacy and efficacy trials\, and on the immune correlates
  studies for several landmark HIV prevention and therapeutic efficacy tria
 ls. In recent years\, she spearheaded fruitful collaborations in bridging 
 the gap between statistical methodology and pharmacometric applications in
  the design and analysis of single and combination HIV monoclonal antibody
  trials. Dr. Huang has published 100+ scientific papers in both methodolog
 ical and applied statistical journals\, as well as in biomedical and pharm
 acokinetics journals.\n            Dr. Huang obtained her B.S. degree in S
 tatistics from the Renmin University of China\, and her Ph.D. degree in Bi
 ostatistics from the University of California\, Los Angeles. \n           
  \n        \n    \n\n&nbsp\;\n
DTEND:20231026T150000Z
DTSTAMP:20260913T044639Z
DTSTART:20231026T140000Z
LOCATION:
SEQUENCE:0
SUMMARY:PSI Vaccine SIG Webinar: A Vaccine Statistician’s Journey in Design
 ing and Analyzing Monoclonal Antibody Studies
UID:RFCALITEM639248715990800024
X-ALT-DESC;FMTTYPE=text/html:<strong>Date:</strong>&nbsp\;Thursday 26th Oct
 ober 2023<br />\n<strong>Time:</strong>&nbsp\;15:00-16:00 BST<br />\n<stro
 ng>Location:</strong>&nbsp\;Online<br />\n<strong>Speaker:</strong>&nbsp\;
 Yunda Huang\, Ph.D&nbsp\;<br />\n<br />\n<p><strong>Who is this event inte
 nded for?</strong>&nbsp\;Statisticians/researchers working in vaccine\, mo
 noclonal antibody or infectious diseases.<br />\n<strong>What is the benef
 it of attending?&nbsp\;</strong>This webinar will help statisticians/resea
 rchers working in the vaccine and monoclonal antibody fields better unders
 tand each other's work and the potential synergies in collaborating with e
 ach other.</p>\n<h4>Registration</h4>\n<p>This event is free to both Membe
 rs of PSI and Non-Members.<br />\nTo register for this event\, please&nbsp
 \;<strong><a href="https://psi.glueup.com/event/86608/" target="_blank">cl
 ick here</a></strong>.&nbsp\;</p>\n<h4>Overview</h4>\n<p>The speaker will 
 share her experience in extending/innovating methodology and concepts deve
 loped in vaccine statistics to the analyses of pre-efficacy and efficacy t
 rials of monoclonal antibodies.</p>\n<h4>Presentation Abstract</h4>\n<p>Ca
 talysed by the rapid research and development of preventive and therapeuti
 c monoclonal antibodies in multiple biomedical fields\, there is an increa
 sing demand of innovative statistical research in the design and analysis 
 of monoclonal antibody studies. Published in 2022\, a new biomarker\, call
 ed PT80 was identified as a promising surrogate endpoint to reliably predi
 ct the ability of broadly neutralizing monoclonal antibodies to prevent ac
 quisition of HIV-1. Findings from this study build on the proof-of-concept
  Antibody Mediated Prevention (AMP) trials showing that an mAb called VRC0
 1 was effective in preventing the acquisition of some &ndash\; but not all
  &ndash\; HIV strains. In this talk\, I will share our journey in reaching
  the discovery of PT80 for VRC01 via extending/innovating methodology and 
 concepts from vaccine statistics to the design and analysis of monoclonal 
 antibody studies.</p>\n<h4>Speaker details</h4>\n<table border="1" cellspa
 cing="0" cellpadding="0">\n</table>\n<table class="table table-striped tab
 le-bordered">\n    <tbody>\n        <tr>\n            <td valign="top" sty
 le="width: 123px\;">\n            <p><strong>Speaker</strong></p>\n       
      </td>\n            <td valign="top" style="width: 479px\;">\n        
     <p><strong>Biography</strong></p>\n            </td>\n        </tr>\n 
        <tr>\n            <td valign="top" style="width: 123px\;">\n       
      <p><img src="https://www.psiweb.org/images/default-source/default-alb
 um/yundaedit.png?sfvrsn=390baddb_0&sf_site_temp=true&sf_site=00000000-0000
 -0000-0000-000000000000" data-displaymode="Original" alt="Yundaedit" title
 ="Yundaedit" /><br />\n            <em>Dr. Yunda Huang</em></p>\n         
    </td>\n            <td valign="top" style="width: 479px\;">\n          
   <p>Dr. Huang&rsquo\;s research areas have focused on the statistical des
 ign and analysis of vaccine clinical trials\, monoclonal antibody clinical
  trials and immunological biomarker studies related to the prevention and 
 treatment of HIV and other infectious diseases. She has worked closely wit
 h academic\, regulatory and industrial collaborators in providing statisti
 cal leadership for 20+ phase 1/2/2b pre-efficacy and efficacy trials\, and
  on the immune correlates studies for several landmark HIV prevention and 
 therapeutic efficacy trials. In recent years\, she spearheaded fruitful co
 llaborations in bridging the gap between statistical methodology and pharm
 acometric applications in the design and analysis of single and combinatio
 n HIV monoclonal antibody trials. Dr. Huang has published 100+ scientific 
 papers in both methodological and applied statistical journals\, as well a
 s in biomedical and pharmacokinetics journals.</p>\n            <p>Dr. Hua
 ng obtained her B.S. degree in Statistics from the Renmin University of Ch
 ina\, and her Ph.D. degree in Biostatistics from the University of Califor
 nia\, Los Angeles. </p>\n            </td>\n        </tr>\n    </tbody>\n<
 /table>\n<p>&nbsp\;</p>\n<br />
END:VEVENT
END:VCALENDAR